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Abstract 
 
The following work addresses the role of podoplanin, a 43kDa mucin-type transmembrane 
sialoglykoprotein, during cutaneous wound healing. The protein participates in physiological 
and pathological processes like development of the lymphatic system and tumour invasion. 
During these events podoplanin seems to increase cellular motility and tissue invasion. 
However, the exact biochemical function of the protein is still unclear.  
In this study podoplanin knock-out and podoplanin wild-type mice were wounded using 
different excisional wound models. To assess the consequences of podoplanin deficiency 
during wound healing, I quantified the size of the wound area and the degree of wound 
contraction by image analyses of macroscopic images. Antibody stainings and fluorescent 
microscopy provide an impression of molecular significance of podoplanin expression at the 
wound site.  
I was able to identify podoplanin in basal keratinocytes and fibroblasts, in a wide area within 
and around excisional wounds during the whole course of reepithelialization. Podoplanin 
deficiency seems to lead to delayed wound healing. However I was not able to observe any 
difference between podoplanin-/- and podoplanin+/+ mice concerning epidermal invasion. 
Furthermore accelerated wound healing in podoplanin+/+ mice is characterized by increased 
wound contraction. So, I assume that podoplanin has an increasing effect rather on wound 
contraction than on reepithelialization. This could be confirmed histologically.  Preliminary 
experiments suggest that increased wound contraction could be the result of podoplanin 
dependent reorganization of the actin cytoskeleton of basal keratinocytes and wound 
fibroblasts. 
Many further experiments will be necessary to clarify the exact role of podoplanin during 
wound healing processes. The investigations on this topic will definitely help us to understand 
the role of podoplanin during embryonic development and tumour progression. 
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Zusammenfassung 
 
Die vorliegende Arbeit befasst sich mit der Funktion welche Podoplanin, ein 43kDa mucin-
artiges transmembranes Sialoglycoprotein während der kutanen Wundheilung erfüllt. Dieses 
Protein ist sowohl an physiologischen als auch an pathologischen Prozessen, wie etwa der 
Entwicklung des lymphatischen Systems oder der Tumorausbreitung beteiligt. Podoplanin 
scheint während dieser Ereignisse sowohl die zelluläre Beweglichkeit als auch die 
Ausbreitung ganzer Gewebe zu fördern. Die genaue biochemische Funktion dieses Proteins 
ist allerdings bisher nicht aufgeklärt.  
In dieser Studie wurden Podoplanin knock-out und Podoplanin Wildtyp Mäuse gewundet, 
wobei unterschiedliche Stanzwundmodelle eingesetzt wurden. Um die Folgen der 
Podoplanin-defizienz während der Wundheilung einzuschätzen, wurden sowohl die Größe des 
Wundareals als auch der Grad an Wundkontraktion mittels Bildanalyse makroskopischer 
Aufnahmen quantifiziert. Antikörperfärbungen und Fluoreszenzmikroskopie bieten einen 
Eindruck von der molekularen Bedeutung von Podoplanin an der Wundstelle. 
Ich war in der Lage Podoplanin auf basalen Keratinocyten und Fibroblasten großflächig 
innerhalb der Wunden zu identifizieren. Dabei konnte die Expression dieses Proteins während 
des gesamten Verlaufs der Reepithelialisierung beobachtet werden. 
Der Verlust von Podoplanin scheint zu einer Verzögerung im Wundheilungsprozess zu 
führen, charakterisiert durch eine verminderte Wundkontraktion. Überraschanderweise war 
ich nicht in der Lage einen Unterschied bezüglich der Einwanderung der Epidermis  zwischen 
Podoplanin-/- und Podoplanin+/+ zu beobachten. Daraus schloss ich, dass das Fehlen von 
Podoplanin eher einen mindernden Effekt auf die Wundkontraktion als auf die 
Reepithelialisierung hat. Dies konnte histologisch bestätigt werden. Erste Experimente  
deuten darauf hin dass die erhöhte Wundkontraktion Resultat einer podoplaninabhängigen 
Umstrukturierung des Aktincytoskeletts von basalen Keratinocyten und Wundfibroblasten 
sein könnte. 
Viele weitere Experimente werden notwendig sein um die genaue Rolle von Podoplanin 
während der Wundheilung aufzuklären. Die Untersuchung diese Gebiets wird uns sicher 
helfen, die Rolle von Podoplanin während der Embryonalentwicklung und der 
Tumorausbreitung zu verstehen. 
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1. Introduction 
 
1.1 Podoplanin 
 
During the last decades our knowledge about and our interest in a protein called podoplanin 
have increased, because of its potential role in tumour invasion. Although the biological 
mechanism of realizing its function is hitherto not known, we have gained in knowledge 
about its chemical structure, expression, localization, interaction partners and the 
consequences of its activity. 
Podoplanin was first described as a 43 kDa protein on the membrane of podocytes of the 
kidney by a group around Dontscho Kerjaschki1. Further studies by the same group revealed 
that the loss of podoplanin function leads to rapid flattening of these podocytes and it was 
postulated that podoplanin is important to for this cell type to maintain its cellular shape2. 
In the following, more and more was discovered concerning the molecular nature of 
podoplanin. So, it was revealed that it is a mucin-type transmembrane sialoglycoprotein 
which is expressed on lymphatic endothelial cells (LECs), but not in vascular endothelial 
cells3. For the development of the lymphatic system podoplanin is of tremendous importance 
and lymphatic endothelial cells (LECs) express podoplanin throughout the whole life of a 
mammalian organism.  Furthermore podoplanin is found on the surface of various tumour 
cells, for example in tumours of the CNS4, squamous cell carcinoma5, Kasposi’s sarcoma6, 
angiosarcoma7 or testicular germ cell tumours8. In all of these cancers a direct correlation can 
be observed between podoplanin expression and the invasion potential of the tumour, which 
suggests a possible connection between podoplanin and cell motility. 
In fact, a huge number of studies prove a correlation between podoplanin and a spread cellular 
shape and a higher migratory potential. In this respect podoplanin is mainly observed during 
physiological processes in which a higher invasion is required. So far, not much is known 
about the way this rather small protein participates in processes determining cell-shape and 
the migratory behaviour. Podoplanin does not seem to have any enzymatic activity and to date 
the number of interaction partners is rather small. 
Taken together, three main processes are known in which an appearance of podoplanin can be 
observed: 
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1. Separation between lymphatic and blood circulation during mammalian embryonic 
development. 
2. Tumour invasion; in the specific types of cancer mentioned above. 
3. Wound healing; at the basal layer of keratinocytes of newly formed epidermis and 
dermal fibroblasts around the wound area  
 
In the following we will discuss all of these physiological processes in context of podoplanin, 
in order to get an image of the workings of this protein. Probably to date, the function of 
podoplanin is best understood during lymphatic development although most time and effort is 
spent on understanding the role of podoplanin in tumour progression. About podoplanin in 
wound healing very little is known, especially because of the fact that before podoplanin KO 
mice existed there was no sufficient procedure to analyze wound healing in the absence of 
podoplanin. 
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1.2 Development of the lymphatic circulation 
 
The lymphatic vasculature consists of a network of blind-ended, thin-walled vessels 
traversing the whole body to drain and to recycle the protein-rich interstitial fluid, from the 
extracellular space back into the blood. This so called lymph fluid reaches the blood 
circulation via the thoracic duct, which connects the blood system with the lymphatic 
vasculature. Beside this function, lymphatic vessels are responsible for the transport of white 
blood cells and dendritic cells from the periphery to the lymphoid organs. 
Both functions are guaranteed by the loose contacts between lymphatic endothelial cells 
(LECs) and the lack of a continuous basement membrane, which facilitates the uptake of large 
macromolecules and migrating cells9. 
The development of the lymphatic vasculature starts later than the development of the blood 
vascular system, referring to this it was worthwhile to study if the lymphatic system arises 
from the blood vessels, already developed in the early embryo. In fact, already 1902 it turned 
out that endothelial cells bud from veins to develop lymphatic sacs, which sprout their cells to 
form the lymphatic vasculature during embryonic development10.   
In mice the development of the lymphatic vasculature starts around day 9 with the expression 
of lymphatic vessel endothelial hyaluronan receptor I (Lyve1), on blood endothelial cells of the 
cardinal vein11. Interestingly, deletion of Lyve1 during embryogenesis does not affect the 
development of a normal lymphatic vasculature, so it is assumed that another, factor 
determines lymphatic development out of the blood vasculature12.  
New insights into LEC specification revealed the transcription factors COUP-TFII and Sox18 
are promising candidates for the initiation of LEC development.  Around embryonic day 
ED9.5 cells on one side of the cardinal vein begin to express prospero-related homeobox 1 
(Prox1). In contrast to Lyve1, Prox1 seems to be of highest importance for the development 
of the lymphatic vasculature, as homozygous Prox1-deficiency leads to a complete lack of 
lymphatic vessels before embryos die at ED14.513. Probably Prox1 is a key player in LEC-
specification, as from this point  Prox1 positive cells start to express various lymph-specific 
markers like neuropilin 2 (Nrp2) or podoplanin14. Development of lymphatic vessels requires 
guided budding of LECs out of the cardinal vein, which afterwards builds up the lymph sacs, 
the origins for the whole lymphatic system of the organism. 
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Figure 1: Development of the lymphatic vasculature9. a | Although Lyve1 is probably the first LEC 
marker expressed on cells of the cardinal vein, it does not seem to have an effect on the normal 
development of the lymphatic vasculature. The unknown factors in the graphic are most likely the 
transcription factors COUP-TFII and Sox18 which induce the expression Prox1. b,c | Expression of 
Prox1 on one side of the cardinal vein leads to occurrence of an LEC phenotype consisting in 
expression of different LEC specific proteins like podoplanin or neuropilin 2. d |  On the action of 
VEGFC LECs bud from the cardinal vein to form primary lymph sacs, which in turn start to sprout 
LECs towards the periphery to act as origins for lymphatic vessels.  
 
The action of vascular endothelial growth factor C (VEGFC) regulates the development of 
blood vasculature and lymphatic vasculature and requires the presentation of VEGF Receptor 
3 (VEGFR3) on the surface of LECs15,16. 
Around ED12 primary lymph sacs develop consisting of LECs originated from the embryonic 
veins, which start to spread throughout the whole body, this leads to formation of the 
functional lymphatic vasculature at around ED14.59. 
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1.2.1 The role of podoplanin in the development of the lymphatic circulation 
 
Since the time point of podoplanin expression in prospective LECs correlates with the 
initiation of LEC budding, one can assume that podoplanin fulfils a function during this 
process. In fact, mice which are deficient in podoplanin expression show blood filled 
lymphatic vessels which indicate a non-separation between the two circulatory systems17.  
During the studies about podoplanin and 
the circulatory separation it could be 
shown that platelets arriving from the 
cardinal vein aggregate between the vein 
and the prospective lymph sac in order 
to mediate their separation. This 
aggregation phenotype could only be 
observed in mice presenting podoplanin 
on the surface of LECs. It was suggested 
that interaction with podoplanin enables 
platelets to aggregate, which in turn 
leads to complete secession of the lymph 
sac. In this case there should be a 
molecular signalling mechanism, 
between podoplanin expressing LECs 
and platelets. Previously it was revealed 
that the C-type lectin-like receptor 2 
(CLEC-2) which is specifically 
expressed on platelets and 
megakaryocytic cell lines, interacts with 
podoplanin18. 
 
 
 
Podoplanin+/+      Podoplanin -/- 
ED16.5                   ED16.5 
        
 
Figure 2: Podoplanin deficiency disrupts 
developmental separation of the lymphatic system 
from the blood vascular system, cognizable by the 
blood filled lymphatic vessels in the skin. 
Podoplanin expression on LECs leads to platelet 
aggregation at the budding position of the primary 
lymph sac. Podoplanin-/- mice do neither show 
this platelet aggregation nor sufficient separation 
between the lymph sac and the cardinal vein17. 
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Clec-2, which was first described as a receptor for the snake toxin rhodocytin, triggers a signal 
transduction pathway including Syk and SLP76 following contact with this toxin19.   
It is likely that interaction between podoplanin 
and CLEC-2 activates the same signalling 
cascade which finally leads to platelet 
aggregation at the separation site.  
Taken together the role of LEC-expressed 
podoplanin during lymphatic development 
consists in activation of platelets arriving from 
blood of the cardinal vein, in order to aggregate 
and mediate lymphatic separation from the 
blood circulation. 
The detailed physiological mechanism of this 
separation is hitherto not known. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
Figure 3: Rhodocytin-CLEC-2 interaction 
activates Platelets via Syk and SLP76. 
Since podoplanin is able to interact with 
CLEC-2 and deficiency in Syk and SLP76 
disrupts lymphatic separation from the blood 
circulation, it is likely that podoplanin-CLEC-2 
interaction triggers the same signaling 
pathway20. 
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1.3 The role of podoplanin during tumour invasion  
 
The transition form a benign resting tumour to a malignant invading tumour is one of the most 
significant reasons for a negative clinical outcome in cancer patients. This transition of tumour 
cells requires changes in their capabilities to adhere, to migrate and to degrade the surrounding 
extracellular matrix (ECM) in order to move from the primary tumour towards peripheral 
tissue. Many events leading to tumour progression are at least partially mediated by the action 
of transmembrane proteins53. These molecules are responsible for functions like cell-cell-
adhesion, cell-matrix-adhesion or for the activation of intracellular signal transduction 
pathways. Integrins for example form connections to the extracellular matrix; molecules called 
cadherins participate in cell-cell contacts. A specific class of cell surface proteins called matrix 
metalloproteinases (MMPs) are proteases which have the ability to degrade extracellular 
matrix. This is important for tumour invasion as well as for wound healing, since in both cases 
cells have to move from one position to another peripheral position21.  
During the last years, a protein of the Cadherin class, the so called E-Cadherin was moved into 
the focus of intensive investigation, as it turned out that its loss on the cell surface supports 
tissue disassembly, cell motility and in consequence tumour metastasis22.    
Several reasons are known for the inactivation of E-cadherin on the cells surface, besides 
mutations, the activation state of the small GTPases Rac and RhoA has effects on the adhesive 
functions of the protein. The activity of these GTPases can change cellular polarity and 
morphology; during this cellular junctions are lost23.  
Rho-GTPases fulfil their functions by reorganizing the actin cytoskeleton. Some of the effector 
proteins in this mechanism are the similar proteins ezrin, radixin and moesin, in short ERM. 
These proteins connect the transmembrane ECM receptor CD44 to the actin cytoskeleton 
which promotes cell motility24. 
Similar to CD44, podoplanin has the ability to interact with proteins of the ERM family 
intracellularly25. In contrast to CD44, nothing is known about any ECM binding function of 
podoplanin and maybe the functions of these two proteins are essentially different.  
In 2006 it turned out that podoplanin, expressed in Madin-Darby canine kidney (MDCK) type-
II epithelial cells, interacts with ERM proteins in order to activate RhoA and to promote 
epithelial-mesenchymal transition (EMT), a process during which epithelial cells acquire 
mesenchymal features, which results in cells with a migratory potential comparable to 
fibroblasts. A complete EMT is often observed in highly aggressive kinds of cancer. The group 
of Ester Martin-Villar pointed out, that MDCK cells which express human podoplanin down-
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regulate epithelial genes like E-cadherin, catenins and cytokeratins and upregulate 
mesenchymal genes like N-Cadherin, vimentin or fibronectin. In consequence the migratory 
behaviour of these cells changes from a rather slow collective migration pattern to a faster and 
individualized. Furthermore it is suggested that the activation of RhoA is a consequence of the 
interaction between podoplanin and ezrin, the RhoA activation in turn promotes epithelial 
mesenchymal transition26. In short, podoplanin on MDCK cells seems to associate with ERM 
proteins at the plasma membrane, which increases the function of RhoA. RhoA activity 
induces cell physiological processes which, in consequence result in epithelial-mesenchymal 
transition (EMT), in order to support cell motility. Concerning cancer, this increased cell 
motility is a risk factor for tumour metastasis and invasion.  
However, in contrast to the results of the group of Ester Martin-Villar in MDCK cells, we will 
see that during tumour invasion podoplanin obviously has the capability to promote migration 
in the absence of epithelial-mesenchymal transition.  
In 2006 the group around Andreas Wicki used transgenic mouse lines, which co-express a 
potent proto-oncogene and podoplanin in the pancreas. 
As expected, mice developed a pancreas carcinoma and podoplanin significantly increased the 
invasive potential of the primary pancreas tumours. Expression of podoplanin on tumour cells 
changes the cellular shape towards a mesenchymal phenotype, as observed during epithelial-
mesenchymal transition. Interestingly podoplanin tumour invasion does not seem to be 
accompanied with the loss E-cadherin at the cell surface. This is surprising, as the loss of E-
cadherin is one of the hallmarks of EMT. Obviously podoplanin enables the cell to become 
invasive without of down-regulation of the E-cadherin levels. As well as E-cadherin also its 
anchor proteins β catenin and p120 catenin, which are normally downregulated during EMT, 
are kept by invading tumour cells expressing podoplanin27. Since E-cadherin requires these 
catenins to fulfil its proper function, one can assume that the whole arrangement for 
establishing adherens junctions is maintained, following podoplanin expression.  
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The need for an EMT without the loss of 
E-cadherin remains elusive. In fact it 
provides the possibility to induce tumour 
cell invasion without dissolving 
epithelial adherens junctions. Otherwise 
it could be advantageous to dissolve and 
re-establish E-cadherin junctions faster 
in some podoplanin-dependent manner. 
Similar results were obtained by Wicki 
et al when they stably transfected MCF7 
breast carcinoma cells with a podoplanin 
expression construct. When these cells 
formed an epithelial layer in vitro, 
expression of podoplanin did not lead to 
loss of E-cadherin on the cell surface but 
to a dramatic change in cellular shape 
and an increased migratory behaviour. 
Like others before, the group emphasizes 
the interaction between podoplanin and 
ezrin. These proteins especially co-
localize at the cell membrane of 
filopodia. This leads to relocalization of 
actin to filopodia. Additionally it could 
be shown, that podoplanin expression 
raises the phosphorylation level of ezrin, 
suggesting that podoplanin affects the 
function of ezrin in a biochemical way. 
This in turn could be caused by 
functional regulation of Rho-GTPases. 
It is known that the concentration of actin at filopodia-like structures can be the result of 
decreased RhoA activity28. In fact it could be shown, by performance of RhoA activity assays 
that the expression of podoplanin leads to downregulation of RhoA activity in MCF7 cells27. 
This is insofar surprising and confusing as this result is contradictory to the results of Ester 
Martin-Villar’s group, which revealed a podoplanin dependent activation of RhoA in Madin-
 
Figure 4: Podoplanin induces tumour 
invasiveness without loss of E-cadherin27 
A-F| Immunohistochemical studies reveal that 
podoplanin expressing tumour cells 
(Rip1Podo;Rip1Tag2) at the invasive front do 
not have to downregulate E-cadherin levels in 
order to gain invasive properties. In contrast, no 
E-cadherin can be detected in podoplanin non-
expressing tumours (Rip1Tag2), these tumours 
probably underwent full EMT. G| Significant 
maintenance of E-cadherin in 
Rip1Podo;Rip1Tag2 tumours compared to 
Rip1Tag2 tumours. 
Tu, Tumour tissue; Ex, exocrine tissue 
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Darby canine kidney (MDCK) cells. At this point it is important to mention that MCF7 cells 
express a high intrinsic level of RhoA, whereas MDCK cells exhibit a low intrinsic activity of 
RhoA29. So, maybe podoplanin regulates RhoA to achieve a specific level of RhoA activation.  
In general, both groups describe the same cellular effect of podoplanin: a podoplanin-
dependent support of migratory capabilities.  
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1.4 Cutaneous wound healing 
 
Wound healing is a physiological process which resembles tumour progression in many 
aspects. Briefly, I want to outline the hallmarks of general cutaneous wound healing processes.  
Oversimplified, wound healing can be subdivided into 3 different phases: 
• Inflammation 
• Tissue formation 
• Tissue remodelling 
At the beginning of the first phase a fibrin clot is formed which serves as temporary wound 
protection and as provisional extracellular matrix for cell migration. This clot consists mainly 
of platelets and mesh of crosslinked fibrin fibers30. As a first line of defence against foreign 
particles, neutrophils enter the wound, followed by monocytes which become activated 
macrophages which fulfil their phagocytic and growth factor releasing functions31. These 
growth factors like TGFα and TGFβ or PDGF (platelet-derived growth factor) support new 
tissue formation32. 
During tissue formation, the most important part is the formation of new epidermis consisting 
of keratinocytes, a process which is called reepithelialization. As these keratinocytes are the 
predominant cells which express podoplanin during wound healing, this cell type is in the 
focus of this study. Keratinocytes are connected to neighbouring keratinocytes by adherens 
junctions called desmosomes and they are connected to the basement membrane by so called 
hemidesmosomes.   Reepithelialization starts with the dissolution of desmosomes and 
hemidesmosomes of keratinocytes33 and the reorganization of the actin cytoskeleton which is 
regulated by the activity of Rho-GTPases34,35. All of these events allow movement of 
keratinocytes into the wound area. Besides migration, keratinocytes now begin to proliferate, in 
order to provide new material for complete wound closure. In general, keratinocytes with a 
high proliferation rate remain behind the actively migrating cells36.   
During invasion of keratinocytes into the wound area, additional fibroblasts move into the 
wound, in order to create new granulation tissue. Macrophages continuously supply the wound 
with growth factors. In a process called neovascularisation new blood vessels grow into the 
wound to ensure the supply with oxygen and nutrients36. 
Approximately one week after injury, when tissue formation slowly ceases, the wound begins 
to reorganize in a process called tissue remodelling. During this fibroblasts turn into 
myofibroblasts by expression of α-smooth muscle actin (α SMA) which forms microfilaments 
along the cytoplasmic face of the plasma membrane. Myofibroblasts are capable to form 
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connections between other cells and the matrix, thus they are able to exert contractile forces 
on the wound leading to wound contraction37. In the end of wound contraction the granulation 
tissue is replaced by a scar, during a process called collagen remodelling, this is characterized 
large highly cross-linked collagen bundles38. 
In general a scar regains at maximum 70% if the strength of normal skin39. 
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1.4.1 Podoplanin is expressed during cutaneous wound healing and other skin 
remodelling processes 
 
Little is known about the cellular processes leading from resting, low-proliferative 
keratinocytes to migrating, high-proliferative cells at the wound margin after injury. Like 
mentioned above, the first steps in reepithelialization require the dissolution of connections 
between neighbouring cells like other keratinocytes (connected by desmosomes) and cells of 
the dermis (connected by hemidesmosomes). After dissociation keratinocytes enter a state of 
increased motility and proliferative activity. All these initial events point to a role of epithelial-
mesenchymal transition in a way we have seen during tumour progression.  
Indeed, there is evidence that keratinocytes at the leading edge of healing epidermis undergo a 
process which is reminiscent of EMT, since these cells express mesenchymal markers like 
vimentin or fibroblast specific protein 1 (FSP1)40. This raises the question if podoplanin 
expression by keratinocytes at the wound margin plays a role during wound healing 
In 1997, a first proof was published, that podoplanin is expressed by keratinocytes in cutaneous 
healing. By introducing a wound into mouse skin, the group was able to stain a protein called 
PA2.26 antigen in the basal region of keratinocytes next to the wound. This protein was later 
found to be identical with podoplanin.  Furthermore the group around Alberto Gandarillas 
found out that not only the keratinocytes of the basal skin layer but even dermal fibroblastic 
cells express podoplanin during tissue regeneration. Already by this point a possible relation 
between podoplanin and cell motility was postulated41. 
 
 
Beside the results concerning wound healing this work clearly shows a connection between 
podoplanin expression and skin carcinogenesis, since the work actually discusses the 
expression of podoplanin on keratinocytes and active fibroblasts during squamous cell 
carcinoma.  
Figure 5: Immunohistochemical 
identification of Podoplanin in 
wound keratinocytes41. 
Podoplanin is solely expressed at 
the high-proliferative basal layer of 
healing epidermis and in dermal 
fibroblasts. Podoplanin = red, the 
arrow marks the site where the 
incision was made. 
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To sum up the results of this study, expression of podoplanin can be observed after cutaneous 
injury, during skin carcinogenesis and following treatment of the skin with phorbol esters like 
TPA. The group points out that all these processes include an increase of cell motility. 
However, podoplanin expression can not be observed in completely untreated skin under 
normal physiological conditions. This suggests a direct role of podoplanin in tissue 
remodelling processes41.   
However, it the role of podoplanin during wound healing was not investigated so far, as no 
work addressing this issue was published to date. 
Nonetheless the results about podoplanin expressing keratinocytes in carcinogenesis are 
interesting and can be considered as the best basis to investigate the role of podoplanin during 
wound healing. In further studies it could be shown also for keratinocytes that podoplanin co-
localizes with ERM (ezrin, radixin, moesin) family members, which leads to a massive 
rearrangement of the actin cytoskeleton towards a fibroblastoid cell morphology. Podoplanin 
obviously redistributes ezrin, to enable an interaction between these two proteins at plasma 
membrane projections like lamellipodia and filopodia. So, a relation between podoplanin and 
cell migration was highly probable25.  To support this notion another study revealed that 
podoplanin which is expressed by MCA3D keratinocytes leads to destabilization of adherens 
junctions mediated by E-cadherin, downregulation of basal keratins, induction of vimentin and 
keratin K8 and the acquisition of a malignant phenotype42. All these events point to a function 
of podoplanin during epithelial-mesenchymal transition in keratinocytes, since the loss of E-
cadherin and the expression of vimentin are critical hallmarks in the transition from an 
epithelial to a mesenchymal state. Very interestingly, RT-PCR to quantify E-cadherin gene 
expression shows only a slight reduction in the transcription of Cadherin mRNA. However the 
functional protein could not be detected performing Western immunoblotting with cell lysates, 
instead several smaller peptides were detected. This suggests that previously functional E-
cadherin proteins were proteolytically degraded, as a result of podoplanin expression. The 
levels of β-catenin however were equally in podoplanin expressing cells and control cells42. 
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These results expand the data obtained by Andreas Wicki et al who discovered that 
podoplanin expression on invasive pancreas tumours leads to maintenance of E-Cadherin 
during invasion. According to this model it is possible that E-cadherin is detectable on the 
surface of podoplanin expressing cells, but the protein is not functional anymore. This result 
is confirmed by another study by a group around Ester Martin-Villar in 200543.  However, this 
model still allows a mechanism of rapid restoration of cell-cell-contacts, compared to cells 
which undergo full EMT by genetic down-regulation of adherens molecules.  
Taken together, podoplanin is expressed on activated keratinocytes. The action of podoplanin 
influences the morphology and the migratory behaviour of keratinocytes during these 
processes and it seems to hold true that podoplanin supports the formation of cell-cell 
junctions during a mesenchymal cellular state.  
By use of squamous cell carcinoma models we were able to gain much insight into the 
function of podoplanin expressed by keratinocytes and we hope that this knowledge will help 
us to understand the role of podoplanin during wound healing. Since the establishment of a 
podoplanin knock-out mouse line by the group around Pavel Uhrin is a very new progress in 
this field, it was not easy in the past to perform in vivo wound healing experiments, in which 
normal wound healing can be compared to podoplanin inhibited wound healing.  
Next, I will briefly describe the establishment of podoplanin deficient mice, which allowed us 
to study the contribution of podoplanin to cutaneous wound healing. 
 
 
 
Figure 6: Left| Quantification of E-cadherin mRNA by RT-PCR. Right| Western 
immunoblotting of cell lysates for E-cadherin Protein. 
Control cells line 1-2, podoplanin transfectants line 3-5 42 
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 1.5 Podoplanin KO mice 
 
In former trials to create podoplanin null mice, the animals died immediately after birth in 
consequence of respiratory failure. This suggests a role of podoplanin during lung 
development. Indeed loss of podoplanin causes anomalies in the development of lung 
alveoli44. Nonetheless a further try by Pavel Uhrin using 129S/v and Swiss mice was finally 
successful creating surviving podoplanin knock-out mice, of this background.   
The podoplanin knock-out mice established by Pavel Uhrin, were generated by disrupting the 
coding region of the podoplanin gene. More precisely, the murine gene for podoplanin 
consists of 6 exons which code for different parts of the protein. Using a targeting vector, the 
group was able to exchange the exons II, III, IV and V by a neomycin phosphotransferase 
cassette in 129S/v embryonic stem cells. Thus the podoplanin gene was completely disrupted. 
The obtained chimeric mice were crossed with C57/Bl6 mice and the disrupted podoplanin 
allele was partially transmitted to the offspring. The thereby generated podoplanin+/- 
heterozygous mice where intercrossed yielding podoplanin-/- mice45.  
 
Figure 7: Disruption of the podoplanin gene by homologues recombination with the 
pPNT.podoplanin targeting vector. Black boxes represent exon sequences. Exons II-V are 
exchanged by the neo gene, upon homologues recombination45. 
  
As mentioned above, previous podoplanin knock-out experiments showed a neonatal death 
rate of 100%, probably because of respiratory failure. Also in this protocol, mice show a 
mortality of around 70% (40% during embryonic development, 55% during the first postnatal 
week). It is hitherto unclear why – in this background - around 20% of the individuals become 
fertile adult animals with normal life spans. 
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 2. Aims 
 
In the present study I want to clarify 
differences in the process of wound 
healing between podoplanin knock-out 
and wild-type mice. For this I am taking 
advantage of the podoplanin knock-out 
mouse strain which was generated by 
Pavel Uhrin, one of my supervisors. This 
should allow a fast and reliable 
approach, to reach my goals. 
By macroscopic and microscopic studies 
I will try to assess specific properties of 
wound healing which are affected by 
podoplanin. 
So far, nobody knows when podoplanin 
is expressed in the course of wound 
healing and identification of a specific 
time window during which podoplanin is 
expressed maybe points to a specific 
function of podoplanin.  
Considering the previous results, 
generated during the last years, one can 
assume that reepithelialization in wild-
type animals happens faster, because of 
an increased invasion potential of 
podoplanin expressing keratinocytes.  
Furthermore, it will be worthwhile to focus on the morphology of invading keratinocytes and 
the organization of the cytoskeleton, as both is obviously dramatically reorganized by the 
presence of podoplanin. 
Herein, I will address both, the function of podoplanin on basal keratinocytes as well as on 
dermal fibroblasts. Since both cell types are of most critical importance for the success of 
wound healing, it is likely that podoplanin fulfils a crucial function during wound healing.  
 
Summary 
 
- Podoplanin is sialomucin typeI transmembrane 
glycoprotein, presented on the surface of LECs, 
cells of various invading tumours and 
keratinocytes and dermal fibroblasts during skin 
remodeling processes like wound healing. 
 
- Podoplanin seems to increase cell motility as it is 
expressed in physiological processes during 
which a higher migration potential is required. 
 
- The interaction between podoplanin and Clec-2 
on platelets is necessary for separation of blood 
and lymphatic circulation during embryonic 
development. 
 
- During tumour invasion of specific cancers, 
podoplanin can be detected at the invasive front. 
There, it is suggested to increase the invasive 
potential during maintenance of cell-cell junctions. 
 
- So far, nothing is known about the mechanisms 
concerning podoplanin expression on basal 
keratinocytes and dermal fibroblasts following 
injury. Investigating this is in the focus of this 
study. 
 
- Podoplanin interacts with the actin-cytoskeleton 
via proteins of ERM (ezrin, radixin and moesin) 
family (especially ezrin). This interaction leads to 
re-localization of all of its components to 
migratory structures like filopodia. 
 
- Expression of podoplanin probably triggers 
incomplete epithelial-mesencyhmal transition 
which allows the formation of cell-cell-contacts via 
cadherins during migration processes. This could 
lead to collective migration of whole tissue 
sheets. 
 
- Recently, podoplanin knock-out mice could be 
established. Although with a death rate of 70% 
during embryonic and early postnatal 
development. 
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3. Materials and Methods 
 
3.1 Scratch wound assay 
 
Sterile fibronectin coated glass cover slips (Marienfeld Micro Cover Glasses) were provided by 
Johannes Breuss and fibroblasts were a gift from Hannes Stockinger. A circular silicone frame 
was applied on the cover slip using a brush and Baysilone-Paste (GE Bayer Silicones). Cover 
slips were put into 6-well-plates. NIH3T3 fiborblasts (NIH3T3WT) and podoplanin transfected 
NIH3T3 fibroblasts were diluted to final concentration of 300cells/µL in RPMI medium with 
10% serum and penicillin/streptomycin. 100µL of the cell suspensions were applied into the 
circular frame. Cells were cultivated until confluence over night at 37°C and 5% CO2. The 
cover slip was fixed onto a metal plate showing a circular recess right at the position of the 
circular cell layer, medium was changed. A scratch was introduced into the middle of the cell 
layer using a pipette tip (for 200µL) and another cover slip was fixed onto the other side of the 
recess. The whole construct was inserted into an Olympus AX70 microscope and images of the 
scratch wound were taken automatically every 8 minutes for 3 hours.  
 
3.2 Excisional wound model 
 
3 to 6 months old podoplanin wild-typ and knock-out mice of the same sex were transferred 
into separate cages, providing enough water and feed. Mice were anaesthetized 2.5 parts 
Ketasol (Graeub), 1 part Rompun (Bayer), and 6.5 parts sterile destilled water (Mayrhofer 
Pharmazeutika). For every 10 grams of mouse weight 75µL anaesthetic were injected under the 
abdominal skin.  
Fully anaesthetized mice were shaved on the back near the forelegs using 70% Ethanol and a 
conventional razor blade (Gilette). Two 6mm circular excisional wounds were marked using a 
sterile 6mm biopsy puncher (kai medical). Skin was lifted inside the mark using sterile forceps 
and excised around the trace using sharp and sterile scissors. 
Wounds were photographed using a stereo microscope (Olympus 3100), a Sony DSC W200 
digital camera and a ruler close to the wound; mice were transferred back into the appropriate 
cages. Every 24 hours mice were anaesthetized by isofluoran inhalation (lasts for 
approximately 1 minute) and wounds were photographed as described. 
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In the end, mice were sacrificed softly by isofluoran inhalation, photographed and shaved again 
if required. Wound tissue was excised and frozen in OCT tissue tek using liquid nitrogen. 
Wounds were divided into two equal parts. Embedded tissue was stored on -20°C. 
 
3.3 Tension wound model 
 
This is a modified model of a wound model originally published by Robert D. Galiano46. 
Mice were chosen, kept, shaved and anaesthetized as described before. A hole of 6mm 
diameter was punched into a 0.5mm thick Press-to-seal silicone sheet (invitrogen) using a 6mm 
biopsy puncher, a silicone ring was circularly excised from the whole silicone sheet around 3-
5mm outside of the inner hole edges, using conventional scissors. This results in a silicone 
torus with a hole- diameter of 6mm and a full diameter 12-16mm. Two of these silicone 
constructs were stitched onto the same positions the excisional wounds were introduced. For 
this, 8 sutures in equal distances fix the silicone ring on the back skin of the mice; thereby the 
skin was gently pulled from an inward position underneath the silicone toward a rather outward 
position, this slightly tense skin was then fixed to the silicone by a suture.  
Inside each silicone structure, a 4mm circular excisional wound was traced using a sterile 4mm 
biopsy puncher. Skin was lifted inside the trace using sharp sterile forceps (because tense skin 
is harder grasp) and excised around the trace using sharp and sterile scissors. Mice were 
photographed and sacrificed as already described. The silicone torus was removed by cutting 
the sutures and the wound tissue was treated as described. 
 
3.4 Histology 
 
8µm transversal cryosections were produced starting directly at the division site of the wound, 
using a MICROM HM 500 OM cryostat. Sections were stored at -20°C if not immediately 
needed, or at least air-dried for 30 minutes for immediate use.  Tissues were fixed and 
histological staining was performed using Hemacolor rapid staining (Merck Chemicals), 
according to users manual. Stained tissues were air-dried and embedded using Entellan Neu 
(Merck Chemicals). 
 33 
3.5 Immunofluorescence 
 
8µm cryosections which were stored at -20°C were fixed for 2 minutes in -20°C acetone. OCT 
Tissue Tek surrounding the tissue was washed away using mains water, for at least ten 
minutes. Slides were inserted into Shandon Coverplate™ apparatur and equilibrated with 
50mM Tris/HCl buffer. Unspecific protein binding sites of the tissue were saturated with 2% 
normal goat serum (Dako) for 20 minutes. Primary antibodies were optimally diluted in 
Antibody Diluent (Dako) and slides were incubated with appropriate primary antibody 
dilutions (see table below) over night at 4°C. Slides were washed three times with 50mM 
Tris/HCl. If required, secondary antibodies were optimally diluted in Antibody Diluent (Dako). 
Slides were incubated with secondary antibody dilutions (see table below), for 30 minutes. If 
required, streptavidin was optimally diluted in Antibody Diluent and slides were incubated 
with streptavidin solutions for 5 minutes. Nuclei were counterstained with Hoechst (Molecular 
Probes). Samples were washed three times with 50mM Tris/HCl and mounted in Ultramount 
(Lab Vision Corporation) 
 
Antibody or staining compound µg/mL Dilution Incubation 
Primary antibodies    
Hamster anti mouse Podoplanin (Acris) 3.3 1/150 o/n 
Rabbit anti mouse Ki67 (NeoMarkers) 5 1/150 o/n 
Biotin conjugated anti mouse CD41 (eBioscience)  5 1/100 o/n 
Rabbit anti mouse Lyve1 (abcam) 5 1/200 o/n 
Secondary antibodies    
Biotin conjugated rabbit anti hamster (Acris) 4 1/500 30’ 
Alexa Fluor 555 goat anti rabbit (invitrogen) 4 1/500 30’ 
Staining compounds    
Hoechst (Molecular Probes) 10 1/1000 30’ 
TRITC Phalloidin (Sigma-Aldrich) 5 1/200 30’ 
Alex Fluor 555 Streptavidin (Molecular Probes) 3 1/500 10’ 
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3.6 Microscopy and image analysis 
Microscopic images of histological and immuonfluorescent stainings were taken with a 
motorized Olympus AX70 microscope by 10x, 20x and 40x UplanApo air objective lenses and 
using a cooled F-View II Camera. Image analysis was performed using CellP imaging software 
(Olympus Soft Imaging Solutions).  
 
3.7 Statistical analysis 
Statistical significance was calculated by unpaired t test and log rank test using GraphPad 
Prism software. Significance was assigned to P values less than 0.05. 
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4. Results 
 
4.1 Podoplanin leads to increased and collective cell migration 
 
In my first experiment I wanted to know if the expression of podoplanin has any consequence 
on the migratory behaviour of cells. According to the literature27 podoplanin expressing cells 
should show an increased and more collective motility than cells which do not express this 
protein. As we unfortunately failed to cultivate fibroblasts or keratinocytes from WT and 
podoplanin KO mice, we compared NIH3T3 wild-type fibroblasts and NIH3T3 podoplanin 
transfected fibroblasts in a scratch wound assay, the cells were a generous gift of Hannes 
Stockinger.  
WT (NIH3T3) and podoplanin over-expressing (NIH3T3PodoOE) fibroblasts were seeded on a 
fibronectin matrix and cultivated until confluence was reached. A scratch was introduced into 
the cell layer using a pipette-tip and “healing” of the scratch was monitored for the following 
three hours. 
 
 
 
First, we observed that scratch wounds of WT and podoplanin over-expressing (PodoOE) cells 
differ right from the beginning. The scratch through WT cells seems to be straight and smooth, 
whereas it seems to be ruffled and uneven in case of PodoOE cells. Probably podoplanin 
Figure 8: Scratch wound assay on 
fibronectin using WT and 
podoplanin over-expressing NIH3T3 
cells. After 3 hours NIH3T3PodoOE 
cells show increased and more 
collective migration into the scratch 
compared to NIH3T3 WT cells.  
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supports intracellular cell-cell contacts already in the state of confluence. Therefore some of 
the cells which are affected by the scratch remain attached to the adjacent scratch margins and 
re-enter the scratch immediately.  
Furthermore, we observed an increased and collective migration in PodoOE samples compared 
to WT. These results are consistent with the position that podoplanin supports cell migration 
and contributes to maintenance of cell-cell interactions during migration processes. 
If we assume that cells which express podoplanin during wound healing behave in a similar 
way, it is imaginable that podoplanin has a supportive effect on the collective invasion of 
epidermal keratinocytes into the wound area.   
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4.2 Podoplanin is expressed during the full process of reepithelialization  
 
Next, I wanted to examine when and by which cell types podoplanin is expressed, during 
cutaneous healing. According to the studies of Gandarillas et al41, podoplanin is expressed at 
least 48 hours after wounding in basal keratinocytes and dermal fibroblasts near the wound 
margins. With this experiment I wanted to confirm these results and I performed a study to 
reconstruct a time course, for the expression of podoplanin during wound healing. For this, I 
sacrificed wounded WT mice every 24 hours, from day 1 until day 8 and checked the wounds 
for podoplanin expression, using a monoclonal antibody against this protein on 8µm tissue 
sections. 
Fluorescence microscopy reveals, that podoplanin is expressed in basal keratinocytes, during 
the whole course of reepithelialization, which starts at around day 2 and lasts until around day 
8. However, podoplanin seems to disappear from these cells after complete epithelialization 
of the wound area, which is achieved approximately at day 8 (see figure 9). This suggests a 
role of podoplanin which is not restricted to any distinct phase of wound healing, like the 
inflammatory phase in the beginning or tissue remodelling in the end of the healing process. 
Therefore it is worthwhile to consider a role of podoplanin during rather general aspects of 
healing epidermis, like keratinocyte migration, proliferation or wound contraction.  
The expression of podoplanin seems to reach a peak between day 4 and day 6, during 
maximum proliferation and reepithelialization.  
In general, we can confirm the observations of Gandarillas et al, as we obtain a positive signal 
for podoplanin in both, basal keratinocytes and fibroblasts within the dermis. Additionally, 
fibroblastoid structures within the granulation tissue were positive for podoplanin (see figure 
9; day 5). This could point to a role of podoplanin in recruited fibroblasts at the site of injury 
in order to support development of provisional matrix and wound contraction. 
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Figure 9: Podoplain is expressed in the basal keratinocyte layer of healing epidermis, 
throughout the whole process of reepithelialization. The figure shows podoplanin stainings for 
every 24 hours from day 1 until day 8. At around day 8 the whole wound area is covered with a newly 
formed keratinocyte layer. Podoplanin expression in basal keratinocytes of healing epidermis seems 
to last throughout the whole sequence of reepithelialization. At the end of epidermis formation 
podoplanin expression seems to cease, until it is almost completely gone at around day 8 (successful 
staining for podoplanin at day 8 is indicated by podoplanin+ lymphatic vessels P+LV in the sample)     
 
 
           day 1            day 2 
           day 3            day 4 
           day 5            day 6 
           day 7            day 8 
 P+LV 
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4.3 Podoplanin is expressed in healing epidermis also distant from the invading front 
 
Interestingly, I was able to detect podoplanin not only at the invading front of the epidermis, 
but along the whole migration distance, from the initial wounding site to the invading edge of 
the epidermis (see figure 10). This result makes it difficult to believe in a function of 
podoplanin which is restricted solely to the invading front of the forming epidermis, as 
described for invading tumours.   
 
 
 
Figure 10: Day 4 wounds clearly show expression of podoplanin (red) in the basal keratinocyte layer 
(white arrow). The pale, green area above the basal layer shows the full thickness of the keratinocyte 
layer. Obviously, podoplanin is expressed even at locations far away from the actual migration front of 
the keratinocyte sheet (red arrow) and affects even areas between the first hair roots behind the 
wound area (green arrow). Podoplanin positive fibroblastoid cells within the granulation tissue are 
indicated by a yellow arrow. 
D dermis; ED epidermis; GT granulation tissue. 
 
Distinct expression of podoplanin can be even observed in pre-existing epidermis after 
wounding. The hair roots which are indicated by green arrows are parts of pre-existing 
epidermis at the wound edge, and we can see a clear expression of podoplanin in basal 
keratinocytes, between these hair roots. The epidermal areas behind these hair roots show that 
podoplanin expression is not a general phenomenon of basal keratinocytes, since these areas 
do not express the protein. So, we can assume that the signals (still unknown) which trigger 
the expression of podoplanin even affect areas, which do not directly belong to the invasion 
site (red arrow). This in turn, leads to the assumption, that podoplanin is active during 
general, basic rearrangements of the epidermis.  
To date we do not have any explanation for the presence of podoplanin in these distant areas. 
As hair roots supply the wound with additional keratinocytes derived from stem cells, one 
possibility could be that podoplanin plays a role during keratinocyte migration or proliferation 
to supply the invasive front with additional cells.     
  
Podo+/+ day 4 
D 
ED 
GT 
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4.4 Podoplanin-/-  mice show impaired wound healing in macroscopic studies 
 
Keratinocytes of the basal skin layer and dermal fibroblasts around healing wounds show 
remarkable expression of podoplanin, which we do not observe in healthy unwounded skin. 
The basal skin layer is the migratory and proliferative active part of the epidermis. Therefore 
one might hypothesize that podoplanin fulfils similar functions during wound healing as during 
tumour invasion and metastasis and podoplanin positive keratinocytes show a higher invasive 
potential into the wound area, than keratinocytes which do not express this protein.  
Comparing wounds of podoplanin wild-type and knock-out mice will allow us, to assess 
differences in the wound healing capacity depending on the expression of podoplanin. 
To get a first idea about these differences, I introduced two 6mm excisional biopsy punch 
wounds onto the shoulders of 7 podoplanin knock-out and 7 wild-type mice, resulting in 14 
wild-type and 14 knock-out wounds. For the wound introduction, only the dermis and the 
epidermis were cut away. These wounds were observed for the following 13 days and pictures 
were taken everyday.  
The first criteria I wanted to analyse, was the time the wounds need to close. Complete wound 
closure was defined as, the development of a bright, pale, scar-like skin surface, from a red and 
crustal wound surface. 
 
 
                      
 
Statistical analysis of the wound closure time for all introduced wounds revealed, that wound 
closure in podoplanin WT mice happens significantly faster (see figure 12). Complete wound 
closure in KO mice seems to be approximately 2 days delayed, as it happens earliest at day 9, 
compared to WT mice which show first events of wound closure already at around day 7. The 
whole batch of WT wounds shows complete closure between day 7 and day 11, whereas KO 
wounds close between day 9 and day 13. 
day 0    day 7        day8 closed! Figure 11: Wound 
closure in an average 
podoplanin Wt mouse. 
At day 8 a blood red 
wound surface was not 
visible anymore and the 
wound seems to be 
completely sealed. 
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Figure 12: Statisitcal analysis of cutaneous 
wound closure in podoplanin KO and Wt 
mice. The chart shows the percentage of open 
wounds over time. WT wounds obviously begin 
to close at around day 7 and at day 11 all WT 
wounds are closed. KO wounds begin to close 
at around day 9 and even at day 13 some few 
wounds are not closed yet. 
Wound closure 
WT: n = 14 
KO: n = 14  
p = 0.0001 
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4.5 Podoplanin deficient mice show impaired wound contraction 
 
Subsequently, I wanted to analyze how both types of wounds develop during the course of 
time. For this, two criteria were taken into account: 
 
1. The visible wound area 
2. Change of the wound shape as an indicator for wound contraction 
 
The visible wound area was considered as the red area lacking any obvious epidermal ingrowth 
(brighter, pale area), the change of the wound shape as an indicator for the contraction of the 
wound, was measured as the ratio between the vertical and the horizontal wound extension (see 
Figure 14). For the macroscopic assessment of the wound contraction we hypothesized that the 
skin shows a higher flexibility in the axis from head to detail than around the mouse torso; 
therefore the wounds should become a gap-like like shape as consequence of contractile forces.   
The pictures of the wound healing processes in wild-type and knock-out mice suggest an 
impaired healing progress in podoplanin KO mice. Surprisingly healing of WT wounds seems 
to be characterized by a higher degree of wound contraction (see Figure 15). This is indicated 
by a massive decrease of the wound area (nearly 50%) and by visible distortions of the wound 
shape in wounds of podoplanin+/+ mice already at day 2. Podoplanin seems to influence the 
initial phase of wound contraction, which basically depends on immigrated fibroblasts and the 
polymerization of actin into F-actin within these cells47. As I mentioned before, podoplanin can 
be detected at dermal fibroblasts during skin remodelling and it might play a role during 
fibroblast migration into the wound area41.  
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Figure 13: Comparison of wound healing in podoplanin KO and Wt mice. Mice were wounded 
(6mm biopsy punch wound) and healing was observed for 13 days, photos were taken every 24 hours. 
KO mice seem to show impaired wound healing, which could be due to decreased wound contraction. 
Furthermore some knock-out animals show efflux of a transparent fluid (white arrow), this could 
indicate malfunction of lymphatic vessels around the wound area. Numbers indicate the day after 
wounding. 
 
                            
 
Figure 14: Image analysis of the wounds measuring the wound area (a) and the ratio between vertical 
and the horizontal wound extension, yellow lines indicate the measurements. µm and µm2 are given 
automatically by the software. 
 
 
 
 
  head       podoplanin  KO     tail 
head     podoplanin Wt     tail 
a b 
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Evaluation of all 28 wounds by image analysis and statistical analysis for every day shows that 
the reduction of the wound area and the appearance of wound contraction are significantly 
impaired in podoplanin KO mice (see Figure 15).  
 
        
Pday2, 3, 4 = 0.0001          pday1, 2 = 0.0001 
 
Figure 15: Statistical analysis of the reduction of the wound area in percent of the original area (a; 
average wound closure) and of the wound contraction. The p values of 0.0001 designate the results as 
significant for the days 2, 3 and 4 in the decrease of the wound area and for the days 1 and 2 in the 
change of the wound shape. 
a: Podoplanin KO mice seem to be impaired in decreasing the size of the wound area, starting at the 
very beginning. 
b: Wounds of podoplanin KO mice show a lesser degree of changing the wound shape which indicates 
impaired wound contraction, especially in the very first and the last part of wound healing. 
  
 
As we can see in the left chart, the decrease of the wound area over time is homogenous in 
both, podoplanin knock-out and wild-type mice. This decrease is indeed faster in wild-type 
mice, and basically wound healing in both types of mice show a rather linear healing process. 
Concerning wound closure we see the biggest difference at day 4 after wounding, a time point 
where the level of reepithelialization and the expression of podoplanin are highest. After that 
time point wound healing in knock-out mice seems to catch up, until wound closure in wild-
type increases again between day 8 and day 9. This increase can not be explained by 
reepithelialization, as the production of new epidermis is either completed or really subsided 
at that point (indicated in figure 9). An event during wound healing which often coincides 
with day 7 or day 8 is the switch from fibroblasts to myofibroblasts, which function as the 
contractile element during the end of wound healing36. So, the significant decrease of the 
a b 
 
WT: n = 14 
KO: n = 14  
average wound area % wound shape change 
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wound area in wild-type mice compared to knock-out mice could be due to an increased 
fibroblast and myofibroblast activity.  
The right chart shows the effect of contractile forces on the overall shape of the wound in KO 
and WT mice. The degree of contraction by this measure is most prominent between day 1 
and 4 and day 7 to 9, the latter phase of contraction coincides with the transformation of 
fibroblasts into myofibroblasts. Both podoplanin WT and KO mice show a similar time-
course of wound contraction during the observation period, however in KO mice this 
contraction seems to happen at a lower level. The sequence of contraction events resembles 
the population of the wound with contractile cells, as described in the literature. During the 
first 5 days after wounding, fibroblasts mainly contribute to wound contraction, after that day 
myofibroblasts appear which leads to the highest state of wound contraction47. 
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4.6 Impaired wound contraction in podoplanin-/- can be confirmed by histological studies 
 
To confirm the fact that podoplanin expression contributes to wound contraction, I analyzed 
histological samples of day 4 excisional wounds. For this, 5 WT and 5 KO animals (1 KO 
animal was lost at day 2) were prepared by introduction of 2 6mm circular excisional wounds 
per animal. At day 4 10 WT wounds as well as 8 KO wounds were harvested and histological 
sections were analyzed by Hematoxylin and Eosin staining and morphometric image analysis.  
Wound contraction was calculated in percent, as the decrease of the distance between the 
margins of the dermis (see figure 19; black lines), which is 6000 µm directly after wounding 
and reduces during wound healing solely by wound contraction activities. 
 
 
 
By this measurement of the wound contraction, it can be shown that podoplanin deficient 
mice have a significantly lower wound contraction potential than podoplanin WT mice. This 
result is consistent with our macroscopic observations. Taken together it seems to be true that 
podoplanin positively influences wound contraction.  
 
 
 
 
 
 
Figure 16: Histological evaluation of 
WT and KO mice significantly shows 
that podoplanin deficiency impairs 
wound contraction. KO wounds 
show an average decrease of the 
distance between the dermal 
margins of about 3%, whereas WT 
wounds decrease by about 20% of 
this distance.  
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4.7 Impaired wound healing in podoplanin KO is not caused by reduced 
reepithelialization 
 
To analyze the definite effect of podoplanin on reepithelialization during wound healing, I 
abolished the contributory effect of wound contraction.  
For this I fixed two plastic rings, each onto one shoulder of one mouse. Into the middle of 
these rings I introduced a 4mm circular wound (see figure 17; 6mm circular wounds are not 
desirable because of the size of the whole construct). In consequence, the plastic rings will 
prevent wound contraction and the process of wound healing is solely restricted to 
reepithelialization.  
 
In the following I will term these wounds as tension wounds. 
 
Figure 17: Generation of tension wounds to prevent wound contraction and to restrict healing 
to reepithelialization. The full procedure is described in Materials and Methods.  
 
Altogether 6 podoplanin-/- and 6 podoplanin+/+ mice were wounded, resulting in 12 wounds for 
each genotype.  After wounding, the wounds were monitored for the following 4 days. Since 
at this time reepithelialization reaches a maximum, mice were sacrificed and the wounds were 
analyzed histologically. 
A macroscopic estimation of the healing progress did not reveal any significant correlation 
between reepithelialization and podoplanin expression (see figure 18).  
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podoplanin-/- 
 
 
 
 
podoplanin+/+ 
 
 
 
 
 
 
To analyze reepithelialization, i.e. the development of new epidermis, I had to terminate 
wound healing at some specific point (day 4) to measure the formation of epidermis 
histologically. 
Sections of podoplanin-/- and podoplanin+/+ wounds were histologically stained using 
Hematoxylin and Eosin (see figure 19) and the newly formed epidermis was measured using 
image analysis. For this the newly formed epidermis was defined as the keratinocyte 
proliferation from the dermal margins to the outermost invasion site of the epidermis. 
I was not able to detect a significant difference in the wound reepithelialization between 
podoplanin-/- and podoplanin+/+ wounds. Although the difference is not significant, it even 
seems that the loss of podoplanin on the cell surface supports reepithelialization (see figure 
20). If this comes true, this would be very surprising as it is broadly accepted that podoplanin 
supports cellular invasion, which should actually lead to the opposite effect. 
Figure 18: A macroscopic 
example of podoplanin+/+ and 
podoplanin-/- tension wounds. An 
obvious difference between these 
wounds can not be observed. 
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Figure 19: Histological comparison between podoplanin-/- and podoplanin-+/+ wounds at day 4.  
Green curves: keratinocyte migration distance; red lines: non-epithelialized area; black lines: distance 
between original wound margins after wounding. 
Fluorescent images show podoplanin stainings (red) in the KO and the WT wound.  
D dermis; ED epidermis; GT granulation tissue. 
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Since the statistical evaluation of all 12 KO and WT wounds does not show any significances, 
one can at least postulate that increased wound healing in WT mice is probably not caused by 
an increased level of reepithelialization. Therefore, these results suggest that the function of 
podoplanin in cutaneous wound healing does not consist in supporting migration of 
keratinocytes into the wound area. 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Statistical evaluation of 12 
KO and 12 Wt tension wounds. The 
charts suggest that podoplanin-/- wounds 
reepithelialize at least as fast as 
podoplanin+/+. 
a | distance of newly formed epidermis 
from the original margin towards the centre 
of the wound. 
b | diameter of the area which is not 
covered by new epidermis. 
c | diameter of the wound after excision.   
a b 
c 
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4.8 Podoplanin does not influence keratinocyte proliferation  
 
To assess a possible effect of podoplanin on keratinocyte proliferation I performed antibody 
staining for Ki-67, a protein solely expressed during the cell cycle, which is therefore an 
excellent marker for proliferating keratinocytes. The antibody was used to stain excisional 
wounds 4 days after wounding.  
As indicated in figure 21, we did not see any obvious difference in the amount of proliferating 
keratinocytes in the basal epidermal layer. 
 
 
 
Figure 21: Ki-67 staining (red) for day 4 podoplanin WT and KO wounds. The obtained signal does 
not reveal any relevant difference concerning keratinocyte proliferation. 
 
This and the previous results suggest that podoplanin does not accelerate reepithelialization. 
This supports the hypothesis that podoplanin supports wound healing by influencing a 
different physiological process, likely wound contraction.  
 
   
 
 
 
 
KI-67 DAPI 
+/+ day4 
KI-67 DAPI 
-/- day4 
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4.9 Podoplanin co-localizes with F-actin in basal keratinocytes 
 
As previous studies described, podoplanin is able to interact intracellularly with actin via the 
adapter protein ezrin25. This interaction triggers the appropriate cells to rearrange their actin 
cytoskeleton and to increase their migratory properties. Indeed, this effect was shown for 
carcinoma cells27 and kidney cells26. In this experiment I wanted to find hints on the 
interaction between actin and podoplanin in epidermal wound healing. To make the two 
proteins visible by fluorescence microscopy, I used a monoclonal antibody against podoplanin 
and fluorescence labelled phalloidin, a toxin from Amanita phalloides (death cap), which 
specifically binds actin. 
 
 
Figure 22: Podoplanin co-localizes with actin at the basal membrane of healing epidermis. 
Costaining of podoplanin (red) and actin (green) leads to the assumption that both proteins interact 
with each other, in order to rearrange G-actin towards F-Actin filaments.   
   
The fluorescence images reveal that intense actin staining in healing podoplanin+/+ epidermis 
is solely restricted to the basal epidermal area, where we expect podoplanin expression. In 
fact, co-staining of podoplanin and actin shows that both proteins are clearly present in the 
same cell layer, in wounds of podoplanin+/+ mice.    
ED 
GT 
ED 
GT 
 56 
In contrast to this, in newly formed epidermis of podoplanin-/-, actin seems to be localized 
over the whole epidermal tissue and just a weak concentration of F-actin bundles can be 
observed in the basal region.  
 
The notion that podoplanin affects the organization of the actin cytoskeleton of keratinocytes 
is supported by the fact, that in some cases podoplanin expressing solitary keratinocytes can 
be observed, which reside in higher epidermal layers. In these cells the actin cytoskeleton 
differs remarkably from the surrounding podoplanin non-expressing cells, in terms of 
polymerization of actin into filaments (see figure 23). 
 
actin                           podoplanin               merge                          zoom 
    
Figure 23: Podoplanin seems to lead to intracellular polymerization of actin to F-actin bundles. 
 
According to the literature, podoplanin interacts with actin, in order to promote cell motility. 
Since I could not find any relation between podoplanin expression and increased cell 
migration of keratinocytes, it is likely that the podoplanin mediated rearrangement of the actin 
cytoskeleton fulfils functions beside the support of cell migration. 
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5. Additional Preliminary Results 
 
5.1 Podoplanin possibly participates in interactions between keratinocytes and 
fibroblasts 
 
To analyze molecular differences between podoplanin+/+ and podoplanin-/- mice, concerning 
wound contraction, it is necessary to pay attention on the cells which are mainly responsible 
for this phenotype, i.e. fibroblasts within the wound tissue. The fibroblast density within the 
granulation tissue seems to be high 5 days after wounding. So, I analyzed appropriate 
excisional wounds using a monoclonal antibody against podoplanin and fluorescence labelled 
phalloidin, since the action of wound fibroblasts relies on the function of F-actin. 
actin                                   podoplanin                      merge       
    
         
Figure 24: Actin and podoplanin staining in 5 day Wt and KO wounds. The staining shows 
fibroblasts (white arrows) of the granulation tissue in close vicinity to the dermis. The podoplanin 
positive wound is characterized by a higher amount of fibroblasts which may be orientated to connect 
the upper lying epidermis. 
 
Fluorescent images were taken from the granulation tissue next to the dermis and directly 
below the newly formed epidermis, since this is the region to where fibroblasts migrate into 
the wound area. First of all, we observed a higher abundance and density of wound fibroblasts 
in case of podoplanin positive wounds, this suggests the possibility that podoplanin might 
support an increased collective migration of fibroblasts, as we have seen during my first 
experiment (see figure 24). 
Interestingly fibroblasts seem to directly interact with cells of the epidermis, and the degree of 
interaction seems to correlate with the intensity of podoplanin expression. In case of 
podoplanin negative wounds, we observe a rather unorganized pattern of wound fibroblasts, 
which do not seem to be connected to epidermal cells. Consequently, these observations 
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-/- 
ED 
GT 
ED 
GT 
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suggest that podoplanin possibly plays a role during fibroblast migration into the wound area 
and during association of these fibroblasts with podoplanin expressing keratinocytes.  
There is another possibility which could result in a phenotype which would be characterized 
by an increased amount of fibroblastoid structures right below the podoplanin expressing 
epidermal layer. It could be shown that mesenchymal cells can have an epithelial origin; these 
cells develop in a process called epithelial-mesenchymal transition (EMT). It is known that 
podoplanin supports a process which is reminiscent of EMT. Probably, development of 
fibroblasts out of podoplanin expressing keratinocytes    
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5.2 Podoplanin might play a role in lymphatic physiology after wounding 
 
A secondary finding during this study was the observation, that some KO wounds secrete a 
transparent liquid (see figure 13 white arrow). This liquid really seems to arise from the 
wound, as it can be observed at the same position over a couple of days. These wound 
exudates can be caused by malfunctions of the lymphatic system. If lymphatic vessels do not 
become occluded after injury, interstitial fluid might extravasate from these severed vessels. 
Following injury the coagulation of platelets is an important factor to occlude bleeding blood 
vessels. Additionally platelets have the capability to interact with podoplanin via Clec-2, as 
described above. As lymphatic endothelial cells express podoplanin constitutively, it is 
reasonable to ask, whether platelets which extravasate from severed blood vessels interact 
with podoplanin on severed lymphatic vessels to initiate their sealing. As we have seen in the 
introduction, the interaction between podoplanin on lymphatic vessels and Clec-2 on platelets 
leads to separation of the lymphatic system from the blood vascular system during embryonic 
development. This process ends up in occlusive separation of both circulatory systems. It is 
conceivable that a similar process is initiated by platelets, which enter disrupted lymphatic 
vessels following injury. Elimination of such a physiological process by podoplanin 
deficiency might explain the secretion of fluid by podoplanin KO wounds. 
To investigate this hypothesis, I stained wound tissue sections 3 days after wounding, using 
antibodies against Lyve-1, a general marker for lymphatic vessels and CD41, a protein 
expressed on platelets. 
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       Lyve-1                           CD41                            merge  
          
         
Figure 25: Lyve-1 and CD41 staining for lymphatic vessels and platelets podoplanin KO and Wt 
mice. The images show dermal areas right beside the wound granulation tissue, where blood from 
severed blood vessels might enter disrupted lymphatic vessels. Platelets possibly lead to similar 
separation and occlusion events in podoplanin expressing lymphatic vessels, as during embryonic 
development. Podoplanin negative tissue clearly shows blood filled lymphatic vessels. 
 
The images were taken from dermal areas in close vicinity to the actual wound area, as this is 
the expected site where platelets could probably enter disrupted lymphatic vessels. 
In fact, lymphatic vessel and platelet staining answer our expectations. Concerning 
podoplanin positive wounds we can see a site where platelets seem to contact a lymphatic 
vessel, in order to initiate lymphatic separation. In any case, we were not able to observe 
lymphatic vessels which were filled with platelets around podoplanin WT wounds. 
A different situation is observable in podoplanin KO mice, where we obtain a clear platelet 
signal from the inside of lymphatic vessels around the wound area. Many of the lymphatic 
vessels near the wound area of podoplanin KO mice seem to be wide open and intact (not 
shown). 
These data could be a good starting point, to investigate the interaction between platelets and 
lymphatic vessels during the wound healing. However, since this is not the focus of this study 
many things remain elusive and should be studied by further experiments. 
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6. Discussion 
 
The fact that podoplanin, a 43 kDa mucin-type transmembrane sialoglycoprotein is present 
on the surface of basal keratinocytes and dermal fibroblasts during wound healing, was 
already described 1997 by Alberto Ganderillas et al41. Surprisingly, hitherto nobody 
described a specific role for this protein in cutaneous healing processes. The cellular function 
of podoplanin and its regulation are still unclear. However, it seems to be a key player in a 
variety of processes during which a higher degree of cell motility is required, for example 
tumour invasion and metastasis as well as developmental processes26,27,17. 
All in all, my studies confirm and expand the results obtained by the group around Alberto 
Ganderillas. Podoplanin is expressed during reepithelialization of cutaneous wounds by basal 
keratinocytes of newly formed epidermis. Also dermal fibroblasts inside the wound area and 
in its close vicinity induce the expression of podoplanin. Our assessment of the time course 
revealed strong induction of podoplanin protein expression in keratinocytes at day 3 post-
wounding and the loss of expression when reepithelialization is completed. Podoplanin can 
not be detected in the intact, normal epithelium. Upon wounding the expression of 
podoplanin becomes induced in the activated epithelium around the wound margins 
including also nearby hair roots.  However interestingly, podoplanin expression can be 
identified at positions of the epidermis behind the actual invasion site. This is insofar 
interesting as it is not consistent with previous observations of invading and metastasising 
tumours, which suggest, that podoplanin is expressed only where tumour cells invade tissues 
of the periphery. The fact that podoplanin is apparently expressed during the whole sequence 
of reepithelialization and the fact that it is expressed over a wide epidermal area which is 
affected by the wound, makes podoplanin to a protein which might participate in a general 
aspect of wound healing. Due to this, it is hard to believe in a restricted function of 
podoplanin during processes like matrix degradation directly at the epidermal invasive front, 
the inflammatory response in the beginning or tissue remodelling in the end of wound 
healing.  
Considering the literature which describes podoplanin as a molecule increasing cell motility, 
it seems likely that keratinocytes at the wound margins - upon expression of podoplanin – 
might gain a higher migratory potential compared to podoplanin deficient keratinocytes and 
this might cause  faster wound closure in case of podoplanin WT mice. Support of this 
expectation was provided by the result that over-expression of podoplanin in NIH3T3 cells 
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increased “wound healing” in the so called scratch wound assay in cell culture. This 
observation is consistent with the results of Andreas Wicki et al27, which describe collective 
invasion of pancreas tumour cells, which are transfected with the coding region of 
podoplanin behind the insulin promoter. Wicki et al mention, that this phenomenon depends 
on the ability of podoplanin expressing cells to migrate by maintenance of cell-cell junctions 
(i.e. E-cadherin). This includes the possibility for the formation of new tissue on a higher 
level of organization, since collective migration allows the invasion of whole cellular sheets 
instead of single cells which have to reorganize into functional tissues. This process is highly 
desirable, to achieve efficient closure of cutaneous wounds.  
By monitoring podoplanin deficient and podoplanin expressing wounds for a period of 2 
weeks, significant differences can be observed. In this macroscopic study, WT wounds seem 
to be completely closed approximately 2 days earlier than podoplanin KO wounds. 
Corresponding to the opinion that podoplanin enhances the migratory potential, we first had 
hypothesized that accelerated wound healing might be caused by a higher motility of 
keratinocytes, which would lead to a higher reepithelialization rate.  
Unexpectedly, we were unable to detect a significant difference in the migration distance of 
keratinocytes from the original wound margins towards the middle of the wound of 
podoplanin+/+ and -/- animals. Nor did we note any gross difference in the organization of the 
newly formed epidermis. 
However, the observation was made that WT wounds are characterized by a higher degree of 
wound contraction. Wound contraction does not depend on reepithelialization, but on the 
action of fibroblasts and myofibroblasts within the granulation tissue47. By macroscopic 
inspection alone it is difficult to decide whether faster wound healing of WT wounds is a 
result of increased development of new epidermis or of increased contraction of the wound. 
Evaluation of histological sections of day 4 excisional wounds confirmed that podoplanin 
expression corresponds to significantly enhanced wound contraction while cell proliferation 
did not differ between wt and knock-out animals. Thus wound contraction seems the likely 
explanation for accelerated wound healing in podoplanin WT mice.  
A modified version of a wound healing protocol by Robert D. Galiano46 gave me the 
possibility to investigate wound healing in the absence of wound contraction. A plastic ring 
which was fixed around the wound stabilized the wound architecture and wound closure 
therefore depended solely on the formation and immigration of new epithelium. Using this 
model I was not able assess any significant macroscopic or histological difference between 
podoplanin KO and WT wounds. And the trend pointed rather to an even slightly higher 
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reepithelialization rates in podoplanin KO wounds. This clearly contradicts our first 
hypothesis that accelerated wound healing depends on a faster epidermis formation. On the 
other hand this finding supports the interpretation that podoplanin influences wound 
contraction.     
In addition I was not able to discern any difference concerning the keratinocyte proliferation 
rate, between podoplanin+/+ and -/- wounds.  
Taken together, podoplanin does not seem to have any direct effect on the keratinocytes 
during reepithelialization processes.  
One of the first insights into the function of podoplanin was the observation that podoplanin 
interacts with the actin cytoskeleton via the adapter molecule ezrin25. I was able to confirm 
that podoplanin leads to rearrangement of the actin cytoskeleton, within basal keratinocytes 
of healing epidermis. However my studies do not reveal any correlation between podoplanin-
dependent actin-rearrangement and increased cellular motility. A connection between the 
rearrangement of the actin cytoskeleton and wound contraction is imaginable, as keratinocyte 
at the wound margins might participate in contracting the wound. 
A related question is, if there is any intercellular connection between keratinocytes of newly 
formed epidermis and (myo-)fibroblasts within the wound granulation tissue. In order to 
promote such a connection, actin rearrangement within these keratinocytes might be 
advantageous. In one of my preliminary results I show, that highly organized fibroblasts of 
the granulation tissue show a closer connection to the epidermis when podoplanin is 
expressed (figure 24). However more work is necessary to confirm these data. 
In the literature, a theoretical basis which explains any connection between podoplanin and 
tissue contraction does not exist, however during the analysis of podoplanin expressing 
wounds in 1997, Alberto Ganderillas et al mention that podoplanin is expressed also in 
dermal fibroblasts. Since fibroblasts and myofibroblasts are the key players in wound 
contraction, a connection between podoplanin expression in fibroblasts and wound 
contraction seems to be plausible. 
In 2008 a group around Akikazu Kawase confirmed that podoplanin is expressed by 
fibroblasts of stromal cancers and that these fibroblasts tend to express α-smooth muscle 
actin, a protein typical for myofibroblasts. The group claims that the presence of podoplanin-
positive α-SMA positive fibroblasts within stromal cancers correlates with a shorter survival 
time for patients, as a result of invasive alterations of the tumour49. Whether there is a direct 
molecular connection between podoplanin expression and the development of contractile 
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fibroblasts and myofibroblasts is yet to be clarified, however there seems to be evidence that 
podoplanin affects these cell types, in some manner. 
The function of fibroblasts and myofibroblasts during wound healing require the formation of 
cell-cell- and cell-matrix-interactions which are intracellularly extended by actin filaments50. 
In this respect, fibroblasts create connections to other cells or to the extracellular matrix 
while they remain in their extended mesenchymal appearance. Right during this process, 
podoplanin might play a crucial role, as the development or the maintenance of a 
mesenchymal phenotype without of breaking up intercellular junctions seems to be 
characteristic for podoplanin expressing cells27.  
Furthermore, it could be shown that fibroblasts and myofibroblasts play crucial roles during 
the invasion of squamous-cell carcinoma. Myofibroblast activity seems to promote collective 
invasion of carcinoma cells51. Squamous-cell carcinoma is one of the best characterized 
tumour models showing a clear podoplanin expression at the invasive front. It could be 
shown that fibroblasts within the stroma of this cancer show podoplanin expression as well41, 
the biological meaning of this fact remains to be clarified. In this respect, it is worthwhile to 
further investigate the connection between podoplanin expression and the development of 
myofibroblasts during tissue remodelling processes. 
If it comes true that fibroblasts which express podoplanin during wound healing rather tend 
to actin rearrangements, α-SMA expression and development of junctional complexes, an 
explanation for decreased wound contraction in podoplanin deficient wound seems to be 
within reach. 
As a high number of studies showed before, expression of podoplanin contributes to a more 
fibroblastoid cellular phenotype. This is insofar interesting as the possibility exists that 
myofibroblasts also arise from epithelial cells which undergo epithelial-mesenchymal 
transition (EMT)52. This raises the question if keratinocytes not only interact with 
myofibroblasts, but turn into this cell type themselves. As podoplanin is able to initiate a 
process which resembles EMT26, it could play a crucial role during such a process. A process 
like this would clarify why both cell types, keratinocytes of the healing epidermis and 
fibroblasts of the dermis and the granulation tissue are podoplanin positive. The transition 
from epithelial cells to myofibroblasts and the potential role of podoplanin could be part of 
future studies, as it would address many questions beyond wound healing. 
In a second preliminary experiment, we investigated, what happens to disrupted podoplanin-
positive lymphatic vessels in the wound area, which might become exposed to platelets from 
disrupted blood vessels. This question is related to the already described activation of 
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platelets by contact with podoplanin. In the setting of wound healing this interaction might 
serve to seal severed lymphatic vessels and could possibly also contribute to cell activation 
by stimulating growth factor release from the activated platelets. According to my 
preliminary results, platelets could work as an occlusion factor for disrupted lymphatic 
vessels reminiscent to the events during embryonic development.  
In this work I was able to show that the expression of podoplanin contributes to accelerated 
wound healing. Comparison of wound healing in podoplanin WT and KO mice on a 
macroscopic as well as on a microscopic level allowed me to assess the effects of podoplanin 
deficiency on specific events during wound healing. Interestingly, it turned out that 
accelerated wound healing in podoplanin WT mice relies rather on increased wound 
contraction than on an increase of the migratory or the proliferative potential during 
reepithelialization. This is insofar surprising as podoplanin was described as a molecule 
which enhances cell motility.  
Many further experiments will be necessary to conclude the herein obtained results. This 
work clearly indicates that future studies should focus on the effect of podoplanin expression 
on fibroblast function as well as on myofibroblast development, to understand the role of 
podoplanin during cutaneous wound healing. 
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